FDA Approves Lapatinib/Capecitabine for Advanced Breast Cancer Subgroup

Publication
Article
OncologyONCOLOGY Vol 21 No 5
Volume 21
Issue 5

US Food and Drug Administration (FDA) approved lapatinib (Tykerb), in combination with capecitabine (Xeloda), for the treatment of patients with advanced or metastatic breast cancer

The US Food and Drug Administration (FDA) approved lapatinib (Tykerb), in combination with capecitabine (Xeloda), for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab (Herceptin). It is the first targeted, once-daily oral treatment option for this patient population. Lapatinib was granted priority review by the FDA in November 2006.

'Significant Breakthrough'

"Tykerb is a significant breakthrough for women with advanced HER2 (ErbB2)-positive breast cancer," said Paolo Paoletti, MD, senior vice president of the Oncology Medicine Development Center at GlaxoSmithKline, the drug's manufacturer. "The data clearly show that this small-molecule, oral, targeted agent, in combination with capecitabine, is effective for women whose disease has progressed on previous therapies, including anthracyclines, taxanes and trastuzumab. . . . We are dedicated to the further study and development of Tykerb in a variety of settings including adjuvant breast cancer as well as in other solid tumor types."

This approval reflects more than 16 years of research, including more than 60 clinical trials and investigator-initiated collaborative research studies. As a targeted therapy, lapatinib is designed to interfere with discrete cellular processes or disease mechanisms prevalent in cancer. As an oral therapy, lapatinib offers added convenience for patients.

Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content